-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that the Shijiazhuang four drugs' dexmedetomidine hydrochloride injection was approved for production in imitation 3 categories
.
According to data from Minai.
September 09, 2021, release of drug approval documents pending receipt
Data show that dexmedetomidine is an α2-adrenergic receptor agonist, which is mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia
.
Sales of terminal dexmedetomidine injections in public medical institutions in China in recent years (unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
Dexmedetomidine hydrochloride injection has been included in the national medical insurance and is a major clinical anesthetic
.
According to data from Meinenet, the sales of terminal dexmedetomidine injections in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years, and it will be close to 4 billion yuan in 2020.
It is worth mentioning that Yangtze River Pharmaceutical Group’s dexmedetomidine hydrochloride injection won the exclusive bid in the centralized procurement of 4+7 and alliance areas, and its market share in China’s public medical institutions has rapidly increased, from less than 1 in 2018.
Source: Meinenet MED2.
In addition, dexmedetomidine hydrochloride injection has 7 companies including Jiangsu Zhengda Fenghai Pharmaceutical, Chenxin Pharmaceutical, Yunnan Longhai Natural Plant Pharmaceuticals, etc.
Source: official website of the State Food and Drug Administration, Mi Nei.